Extended Median Survival by 4.1 Months and Increased 3-Year Survival by 38 PERCENT Compared to Placebo First Active Cellular Immunotherapy for Cancer to Prolong Survival Company to Host Webcast at 5:30 pm ET CHICAGO and SEATTLE, April 28 (HSMN Ne…
Biopharmaceuticals, Oncology
Dendreon, PROVENGE, sipuleucel-T, prostate cancer

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study”
Leave a Comment